Characteristics | Brachytherapy group (N = 74) | MWA group (N = 48) | P value |
---|---|---|---|
≤ 10 mm from hilum/pleura/interlobar fissure Demographics and baseline Sex, no. (%) Male Female | N = 54 34 (63%) 20 (37%) | N = 18 10 (55.6%) 8 (44.4%) | 0.712 |
Mean age (years) Age (years), no. (%) <65 ≥65 Primary tumor location, no. (%) Right colon Left colon Rectum Maximum tumor diameter (cm, mean ± SD) Tumor size, no. (%) ≤3 cm >3 cm Tumor number, no. (%) 1 2 3 Distribution of lung metastasis, no. (%) Unilateral Bilateral | 65.9 ± 6.7 32 (59.3%) 22 (40.7%) 24 (44.4%) 16 (29.6%) 14 (26) 3.9 ± 1.3 30 (51.4%) 24 (48.6%) 12 (22.2%) 26 (48.2%) 16 (29.6%) 34 (63%) 20 (37%) | 61.5 ± 8.2 12 (66.7%) 6 (33.3%) 6 (33.3%) 6 (33.3%) 6 (33.3%) 2.8 ± 0.7 12 (66.7%) 6 (33.3%) 8 (44.5%) 6 (33.3%) 4 (22.2%) 10 (55.6%) 8 (44.4%) | 0.263 > 0.99 0.892 0.067 0.439 0.612 0.712 |
Location of lung metastasis, no. (%) Adjacent to the hilum Adjacent to the pleura/interlobar fissure Lung metastasis, no. (%) Metachronous Synchronous CEA (ng/ml), no. (%) <10 ≥10 Complication, no. (%). Pneumothorax Bronchopleural fistula Pleural effusion Hydropneumothorax Survival LTPFS at 1 year, no. (%) Yes No LTPFS at 3 years, no. (%) Yes No Median LTPFS (months) OS at 1 year, no. (%) Yes No | 28 (51.9%) 26 (48.1%) 38 (70.4%) 16 (29.6%) 18 (33.3%) 36 (66.7%) 16 (29.6%) 10 (18.5%) 0 4 (7.4%) 2 (3.7%) 30 (55.6%) 24 (44.4%) 20 (37%) 34 (63%) 17.4 (95% CI: 8.9–23.1) 40 (74.1%) 14 (25.9%) | 6 (33.3%) 12 (66.7%) 8 (44.4%) 10 (55.6%) 8 (44.4%) 10 (55.6%) 16 (88.9%) 8 (44.4%) 6 (33.3%) 0 2 (11.1%) 8 (44.4%) 10 (55.6%) 6 (33.3%) 12 (66.7%) 16.8 (95% CI: 8.4–22.7) 12 (66.7%) 9 (33.3%) | 0.451 0.235 0.693 0.005 0.706 > 0.99 0.793 0.686 |
OS at 3 years, no. (%) Yes No Median OS (months) > 10 mm from hilum/pleura/interlobar fissure Demographics and baseline Sex, no. (%) Female Male Mean age (years) Age (years), no. (%) < 65 ≥ 65 Primary tumor location, no. (%) Right colon Left colon Rectum Maximum tumor diameter (cm, mean ± SD) Tumor number, no. (%) 1 2 3 Distribution of lung metastasis, no. (%) Unilateral Bilateral Lung metastasis, no. (%) Metachronous Synchronous CEA (ng/ml), no. (%) < 10 ≥ 10 Complication, no. (%) Pneumothorax Pleural effusion Hydropneumothorax Fever Survival LTPFS at 1 year, no. (%) Yes No LTPFS at 3 years, no. (%) Yes No Median LTPFS (months) OS at 1 year, no. (%) Yes No OS at 3 years, no. (%) Yes No Median OS (months) | 26 (48.1%) 28 (51.9%) 22.5 (95% CI: 15.6–32.1) N = 20 8 (40%) 12 (60%) 61.3 ± 6.5 14 (70%) 6 (30%) 6 (30%) 4 (20%) 10 (50%) 7.1 ± 1.5 6 (30%) 8 (40%) 6 (30%) 10 (50%) 10 (50%) 18 (90%) 2 (10%) 10 (50%) 10 (50%) 18 (90%) 10 (50%) 2 (10%) 6 (30%) 0 10 (50%) 10 (50%) 10 (50%) 10 (50%) 16.9 (95% CI: 7.8–23.6) 16 (80%) 4 (20%) 10 (50%) 10 (50%) 19.3 (95% CI: 14.9–34.6) | 8 (44.4%) 10 (55.6%) 20.8 (95% CI: 16.1–33.6) N = 30 16 (53.3%) 14 (46.7%) 56.5 ± 4.8 16 (53.3%) 14 (46.7%) 12 (40%) 10 (33.3%) 8 (26.7%) 2.1 ± 0.5 10 (33.3%) 8 (26.7%) 12 (40%) 14 (46.7%) 16 (53.3%) 26 (86.7%) 4 (13.3%) 16 (53.3%) 14 (46.7%) 16 (53.3%) 8 (26.7%) 2 (6.7%) 0 6 (20%) 20 (66.7%) 10 (33.3%) 14 (46.7%) 16 (53.3%) 20.1 (95% CI: 8.6–23.8) 12 (40%) 18 (60%) 16 (53.3%) 14 (46.7%) 25.3 (95% CI: 14.7–38.3) | > 0.99 0.65 0.688 0.153 0.678 0.596 0.036 0.879 > 0.99 > 0.99 > 0.99 0.088 0.442 > 0.99 0.671 0.099 > 0.99 0.787 |